Table 1 Characteristics of study cohort patients

n

102

29

Age

(years)*

53 (45.5-60)

50 (37.5-57.5)

Sex

Male/Female/total

53/49/102

20/9/29

Weight

(kg)*

77 (64–85)

78 (68.5-86)

BMI

(kg/m²)*

26 (23.1-28.7)

26 (24–28)

Genotype 1a/1b

n;%/n;%

28; 27%/74; 73%

7; 24%/22; 76%

Baseline viral load

(IU/ml)*

1.175 Mio (462,250-3.075 Mio)

1.02 Mio (503,000-4.005 Mio)

Baseline viral load ≤ 800.000 IU/ml

n;%

35; 34%

11; 38%

Baseline viral load ≥ 800.000 IU/ml

n;%

66; 65%

18; 62%

Baseline viral load missing

n;%

1; 1%

0

Liver histology available

n;%

60; 59%

17; 59%

Fibrosis score

Ishak*

4 (2–5)

4 (2–5)

Activity score

Ishak*

8 (6–9)

7 (3–8)

Cirrhosis (fibrosis score Ishak ≥ 5)

n;%

29; 28%

6; 21%

Clinical signs of advanced liver disease, but no histology**

n;%

5; 5%

1; 3%

Treatment naïve

n;%

24; 24%

9; 31%

PEG-IFN/RBV, overall

n;%

58; 57%

14; 48%

PEG-IFN/RBV, non-response⁺

n;%

28; 27%

8; 28%

PEG-IFN/RBV, relapse

n;%

25; 25%

5; 17%

PEG-IFN/RBV, unknown response

n;%

5; 5%

1; 3%

Non-PEG IFN overall⁺⁺

n;%

20; 20%

6; 21%

Non-PEG IFN ± RBV, non-response

n;%

9; 9%

4; 4%

Non-PEG IFN ± RBV, relapse

n;%

9; 9%

2; 2%

Non-PEG IFN ± RBV, unknown response

n;%

2; 2%

0

PEG-IFN 2a/2b

n;%/n;%

96; 94%/6; 6%

27; 93%/2; 7%

RBV baseline dosage

mg/day*

1200 (1000–1200)

1200 (1000–1200)

RBV baseline dosage per body weight

mg/kg body weight/day*

14.6 (14.1-15.65)

15 ± 2.6 (14.4-15.9)

Leukocytes

(/μl)*

5990 (4842–7295)

6645 (5330–8410)

Hemoglobin

(g/dl)*

14.7 (13.8-15.9)

15.3 (14.4-15.9)

Platelets

(thousand/μl)*

186 (143–257)

227 (182–259)

Creatinine

(mg/dl)*

0.7 (0.6-0.8)

0.7 (0.6-0.8)

GFR MDRD

(ml/minute)*

102 (90–119)

112.8 (101.6-126.4)

Total Bilirubin

(mg/dl)*

0.7 (0.6-0.9)

0.7 (0.5-0.9)

Quick

(%)*

105 (95–112)

108 (98–115)

INR

INR*

1 (0.9-1)

1 (0.9-1)

GPT

IU/l*

69 (44–87)

64 (46–97)